{"version":"1.0","type":"link","title":"Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.","author_name":"Chan SL 외","author_url":"https://prs-insight.online/author/Chan%20SL","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/113313","thumbnail_width":1200,"thumbnail_height":630}